TransMedics Group, Inc. TMDX
2 targets with a reported result
Releases of the last 3 yearsThe numbers TMDX said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Revenue Fiscal 2026 |
Given $727.00M to $757.00M release Feb 24, 2026
Kept $727.00M to $757.00M release May 5, 2026
Raised $737.00M to $757.00M release Aug 4, 2026
Raised $764.00M to $774.00M release Nov 5, 2026
|
– | Not reported yet | |
The company's wordsTransMedics expects total revenue for the full year 2026 to be in the range of $727 million to $757 million, which represents 20% to 25% growth compared to the company’s prior year revenue. release Feb 24, 2026 Reiterates full year 2026 revenue guidance to be in the range of $727 million to $757 million release May 5, 2026 TransMedics is raising the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million. release Aug 4, 2026 Raises full-year 2026 revenue guidance to between $764-$774 million, inclusive of approximately $14 million from PAD Aviation release Nov 5, 2026 | ||||
| Revenue (company-defined) Fiscal 2026 |
Given $737.00M to $757.00M release Aug 4, 2026
Raised $750.00M to $760.00M release Nov 5, 2026
|
– | No standard number | |
The company's wordsRaised low end of full-year 2026 revenue guidance, excluding PAD Aviation, to a range of $737 million to $757 million release Aug 4, 2026 (8) Full-Year 2026 Revenue Guidance: Revenue guidance of $764-$774 million, less expected PAD Aviation revenue of approximately $14 million, equals revenue guidance excluding PAD Aviation* of $750-$760 million. release Nov 5, 2026 | ||||
| Revenue Fiscal 2025 (ended Dec 31, 2025) |
Given $530.00M to $552.00M release Feb 27, 2025
Raised $565.00M to $585.00M release May 8, 2025
Raised $585.00M to $605.00M release Jul 30, 2025
Raised $595.00M to $605.00M release Oct 29, 2025
|
$605.49M 10-K filed 2026-02-24 |
Above the range | |
The company's wordsTransMedics expects total revenue for the full year 2025 to be in the range of $530 million to $552 million, which represents 20% to 25% growth compared to the company's prior year revenue. release Feb 27, 2025 Raising full year 2025 revenue guidance to $565 million to $585 million release May 8, 2025 Raising full year 2025 revenue guidance to $585 million to $605 million release Jul 30, 2025 TransMedics is raising the midpoint and narrowing the range of its full year 2025 revenue guidance to $595 million to $605 million, which represents 36% growth at the midpoint compared to the company's prior year revenue. release Oct 29, 2025 | ||||
| Revenue Fiscal 2024 (ended Dec 31, 2024) |
Given $360.00M to $370.00M release Feb 26, 2024
Raised $390.00M to $400.00M release Apr 30, 2024
Raised $425.00M to $445.00M release Jul 31, 2024
Kept $425.00M to $445.00M release Oct 28, 2024
|
$441.54M 10-K filed 2025-02-27 |
Within the range | |
The company's wordsTransMedics expects total revenue for full-year 2024 to be in the range of $360 million to $370 million, which represents 49% to 53% growth compared to the company’s prior year revenue. release Feb 26, 2024 TransMedics is raising its full year 2024 revenue guidance to be in the range of $390 million to $400 million, which represents 61% to 66% growth compared to the company’s prior year revenue. release Apr 30, 2024 TransMedics is raising its full year 2024 revenue guidance to be in the range of $425 million to $445 million, which represents 76% to 84% growth compared to the company’s prior year revenue. release Jul 31, 2024 TransMedics continues to expect revenue for the full year 2024 to be in the range of $425 million to $445 million, which represents 76% to 84% growth compared to the company's prior year revenue. release Oct 28, 2024 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (13 releases since 2024-02-26), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TMDX/export.csv") into a cell.